Breaking News
January 22, 2018 - Specially prepared supplement helps women to run faster, study shows
January 22, 2018 - 3-D Stent Retriever with Aspiration Proves Mettle in AIS
January 22, 2018 - Public health research seeks to understand how natural disasters impact spread of Zika
January 22, 2018 - Research reveals role of nanophenomenon in stimulating bone-repair process
January 22, 2018 - Epilepsy associated with volume and thickness differences in brain matter
January 22, 2018 - Trevena Announces FDA Acceptance for Review of New Drug Application for Olinvo (oliceridine) Injection
January 22, 2018 - A Noteworthy Margin of Error
January 22, 2018 - Firm advances human trials of revolutionary vaccine
January 22, 2018 - Many Indians put away treating orthopedic problems
January 22, 2018 - Cherwell releases new pocket guide to prepared culture media
January 22, 2018 - Huron earns ISO 13485 certification for quality management system
January 22, 2018 - Avion Pharmaceuticals Announces FDA Approval of Balcoltra (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets) Oral Contraceptive
January 22, 2018 - Multi-Gene Test For Early CVD; Neighborhood HF Risk; Novel Testosterone Drugs
January 22, 2018 - Skipping breakfast disrupts ‘clock genes’ that regulate body weight
January 22, 2018 - Creativity May Rely on ‘Teamwork’ in the Brain
January 22, 2018 - NeuroBreak: Alzheimer’s Germ Contest; High Salt Diet May Be Bad for Brain
January 22, 2018 - Diabetics may often fare poorly in hospice care
January 22, 2018 - Performance enhancing benefits of caffeine more apparent for infrequent tea, coffee drinkers
January 22, 2018 - HHS Unveils Framework for Interoperability
January 22, 2018 - More dentists to discuss risks of HPV-related cancers with their patients
January 21, 2018 - Research shows how Zika virus damages placenta to cause malformations in babies
January 21, 2018 - Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
January 21, 2018 - Drug Allergies: Time to Re-Test?
January 21, 2018 - Mitochondrial protein in cardiac muscle cells linked to heart failure, study finds
January 21, 2018 - Women more likely than men to die from a heart attack
January 21, 2018 - Next generation genomic sequencing can help detect pathogens after joint replacement
January 21, 2018 - Gov’t Shutdown Looms as Senate Debates Spending Bill
January 21, 2018 - Emergency Readiness for Older Adults and People with Disabilities
January 21, 2018 - Heart health at risk for Latinas over worries about deportation
January 21, 2018 - Scientists methodically identify genes related to blood feeding and non-biting mosquitoes
January 21, 2018 - Researchers discover potential target genes to halt thyroid cancer progression
January 21, 2018 - Youth with shared residency after parents’ divorce have less mental issues
January 21, 2018 - Sleep Better, Lose Weight? – Drugs.com MedNews
January 21, 2018 - More $$ Needed for Health Emergencies, Senators Told
January 21, 2018 - Gene test to predict breast cancer recurrence less cost effective in real world practice
January 21, 2018 - Study finds rise in number of adolescents receiving psychiatric or neurodevelopmental diagnosis
January 21, 2018 - Reminders can improve immunization rates
January 21, 2018 - A More Personalized Approach to PSA Screening in 2017
January 21, 2018 - T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma
January 21, 2018 - Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
January 21, 2018 - Have Robotics Had a Detrimental Effect on Surgical Residency?
January 21, 2018 - Being bilingual may help autistic children
January 21, 2018 - Metrics Are Not Widespread in Rheumatoid Care
January 21, 2018 - Neuroanatomic abnormalities ID’d in those at risk for autism
January 21, 2018 - Children born with Down’s syndrome have superior genome that compensates for disability
January 21, 2018 - Study finds higher risks for asymptomatic paroxysmal AF patients
January 21, 2018 - The Second Stage of Diet Resolutions
January 21, 2018 - CT Scans Reduce Lung Cancer Deaths … But Among Whom?
January 21, 2018 - ADHD drug use soars among young women
January 21, 2018 - Researchers propose new regulation mechanism linked to action of SirT6 on chromatin
January 21, 2018 - Statins appear to reduce risk of repeated surgery in patients who undergo vitrectomy
January 21, 2018 - Morning Break: Hep A Outbreak Spreads; Tide Pod Challenge; Keeping Lobsters Out of Hot Water
January 21, 2018 - EULAR and ACR present SLE classification criteria at the 2017 ACR/ARHP Annual Meeting
January 21, 2018 - Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
January 21, 2018 - House Passes Funding Bill with 6-Year CHIP Renewal
January 21, 2018 - DASH ranked Best Diet Overall for eighth year in a row by U.S. News and World Report
January 21, 2018 - Dementia study sheds light on how damage spreads through brain
January 20, 2018 - Morning Break: Missing Maria Deaths; N.J. Doc Charged in Wife’s Murder; Viva Vaseline!
January 20, 2018 - No interventions proven to prevent late-life dementia
January 20, 2018 - Judge orders new Olympus trial over superbug death
January 20, 2018 - Don’t Rely on Just One Blood Pressure Test for Kids: Study
January 20, 2018 - Going Off the Deep End About Water
January 20, 2018 - Parental attention can reduce risk of drug abuse in adolescence
January 20, 2018 - Mast Uri System offers efficient and cost-friendly diagnostic solution
January 20, 2018 - International SOS, Chatham House sign partnership agreement to further advance Global Health Security Agenda
January 20, 2018 - Study offers way to predict onset of lung disease in children with cystic fibrosis
January 20, 2018 - C-Suite Must Lead in Ending Sexual Harassment
January 20, 2018 - Researchers find a way to ‘starve’ cancer
January 20, 2018 - Applied math can help predict genesis and evolution of different cancers
January 20, 2018 - UCLA researchers describe herpes virus structure associated with Kaposi’s sarcoma
January 20, 2018 - New study enrolls first patient to evaluate potential of WaveCrest LAAO System
January 20, 2018 - New review explores effects of exposing developing brains to general anesthesia
January 20, 2018 - GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
January 20, 2018 - Weight-Loss Surgery Approaches Offer Similar Results
January 20, 2018 - Free online access to millions of documents on chemical toxicity
January 20, 2018 - CE marked MAST Toxoreagent kit for detection of Toxoplasma antibodies
January 20, 2018 - DNA study sheds light on longstanding puzzle of cell division
January 20, 2018 - Montefiore provides specialized medical care to parents of adopted children
January 20, 2018 - Enzyme discovery provides new horizon of therapeutic opportunities across disease spectrum
January 20, 2018 - New smartphone app successfully enables remote monitoring of surgical wounds
Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s

Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s

image_pdfDownload PDFimage_print

Action Points

  • Upfront treatment with the antibody-drug conjugate brentuximab vedotin (Adcetris) led to significantly better progression-free survival for patients with newly diagnosed advanced Hodgkin lymphoma.
  • The addition of brentuximab to chemotherapy increased rates of neutropenia and peripheral neuropathy, which was manageable in most cases.

ATLANTA — Upfront treatment with the antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) led to significantly better progression-free survival (PFS) for patients with newly diagnosed advanced Hodgkin lymphoma, investigators reported here.

Patients who received the ADC, in addition to standard first-line chemotherapy, had a 2-year PFS of 82.1% versus 77.2% for chemotherapy alone. An interim analysis of overall survival (OS) showed a trend in favor of the brentuximab regimen, but the difference did not achieve statistical significance, according to James M. Connors, MD, of the British Columbia Cancer Agency in Vancouver, and colleagues.

The addition of brentuximab to chemotherapy increased rates of neutropenia and peripheral neuropathy, which was manageable in most cases, Connors said during a presentation at the American Society of Hematology meeting. The study was published simultaneously in the New England Journal of Medicine.

The trial also provided support for omitting bleomycin from chemotherapy when brentuximab is used.

“The (brentuximab) regimen is associated with more myelotoxicity — which can be ameliorated with prophylactic G-CSF — and neurotoxicity — which is largely reversible) than ABVD but substantially less pulmonary toxicity and appears to be more effective for the frontline treatment of advanced-stage classic Hodgkin’s lymphoma,” Connors’ group wrote.

Authors of an accompanying NEJM editorial cautioned that follow-up time for the study was too brief to rule out the possibility of late side effects with brentuximab regimen. However, they gave tentative support for upfront use of the ADC.

“It appears that the addition of brentuximab vedotin to AVD combination chemotherapy … merits consideration as first-line treatment for advanced Hodgkin’s lymphoma,” wrote Daniel Longo, MD, and Vincent T. DeVita Jr., MD, both of Yale Cancer Center in New Haven, Connecticut. “Although the follow-up time has been relatively short the (ADC combination) appears to be more effective than ABVD (and is unlikely to be less effective) and is associated with fewer, more treatable toxicities.”

Outcomes for advanced Hodgkin’s lymphoma improved substantially over the past 50 years, especially after the introduction of ABVD combination chemotherapy (doxorubicin-bleomycin-vinblastine-dacarbazine) more than 40 years ago. However, 25% to 30% of patients have refractory disease or relapse after initial treatment with ABVD, Connors’ group noted. Moreover, bleomycin can cause unpredictable and potentially fatal pulmonary toxicity.

Brentuximab vedotin consists of a monoclonal antibody that targets the CD30 surface antigen — expressed by Reed-Sternberg cells in classic Hodgkin’s lymphoma — to the microtubule-disrupting agent monomethyl auristatin. The ADC has FDA approval as treatment for classic Hodgkin’s lymphoma that does not respond, or recurs after stem-cell transplantation or failure of at least two multiagent chemotherapy regimens. The drug also has approval as posttransplant consolidation therapy for high-risk patients.

The decision to include bleomycin in chemotherapy (ABVD) remains controversial, both in terms of efficacy and added toxicity, particularly pulmonary toxicity. In a phase I trial of frontline therapy for advanced Hodgkin’s lymphoma, brentuximab vedotin combined with AVD chemotherapy led to complete responses in 24 of 25 patients, a 5-year failure-free survival of 92%, and OS of 100%.

Connors presented results from a phase III randomized trials to compare brentuximab vedotin plus AVD chemotherapy with standard ABVD chemotherapy in 1,334 patients with untreated stage III or IV classic Hodgkin’s lymphoma. The trial had a primary endpoint of modified PFS — the time to disease progression, death, or non-complete response and use of subsequent anticancer therapy, adjudicated by an independent review committee.

The study population had a median age of 36, and men accounted for 58% of the patients. Two-thirds of the patients had stage IV disease, 62% had extranodal involvement at diagnosis, and 58% had B symptoms (such as night sweats, weight loss, and fever).

After a median follow-up of 25 months, the brentuximab regimen had resulted in a 23% reduction in the hazard for the primary endpoint (95% CI 0.60-0.98, P=0.03). The preliminary survival analysis showed that 28 patients ion the brentuximab arm died versus 39 in the ABVD arm, which translated into a nonsignificant 28% reduction in the hazard ratio in favor of brentuximab (95% CI 0.44-1.17, P=0.19).

With respect to safety, the most common adverse event in both groups was neutropenia, which occurred in 58% of the brentuximab arm and 45% of the ABVD arm. Febrile neutropenia occurred in 19% and 8% of the brentuximab and ABVD groups, respectively. In the brentuximab arm, febrile neutropenia occurred less in of 83 patients who received prophylactic G-CSF (11% vs 21%). Connors said 1% of patients in each group discontinued because of febrile neutropenia.

Other common adverse events (any grade) were infection (55% vs 50%), constipation (42% with brentuximab, 37% with ABVD), vomiting (33% vs 28%), fatigue (32% in both groups), peripheral sensory neuropathy (29% vs 17%), diarrhea (27% vs 18%), pyrexia (26% vs 13%), abdominal pain (21% vs 10%), and stomatitis (21% vs 16%). Neutropenia (54% vs 39%) was the only grade 3 adverse event that occurred in more than 5% of patients in either group.

Pulmonary toxicity occurred in 2% and 7% of the brentuximab and ABVD groups, respectively, including grade ≥3 pulmonary toxicity in 1% and 3%.

The study was supported by Seattle Genetics and Millennium Pharmaceuticals.

Connors disclosed relevant relationships with Janssen, Genentech, NanoString Technologies, Merck, F Hoffmann-La Roche, Cephalon, Seattle Genetics, Bayer Healthcare, Bristol-Myers Squibb, Takeda, Amgen, and Eli Lilly.

Longo disclosed serving as deputy editor of the New England Journal of Medicine. DeVita disclosed no relevant relationships with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-12T00:00:00-0500

last updated

Tagged with:

About author

Related Articles